From: Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry
Type of Adverse Events
Clinical Adverse Events*
N = 103
n (%)
Laboratory Adverse Events**
Any adverse events
4 (3.9)
8 (7.8)
Serious adverse events
3 (2.9)
1 (0.9)
Serious adverse events leading to discontinuation
2 (1.9)